Dan Chen1,2,3,4,5,6, Xiaoling Peng7, Yu Zhan8, Peng Wu1,2,3,4,5, Li Jiang1,2,3,4,5, Yue Hu9,10,11,12,13. 1. Department of Neurology, Children's Hospital of Chongqing Medical University, No.136 Zhongshan 2nd Road, Yu Zhong District, Chongqing, 400014, China. 2. Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China. 3. National Clinical Research Center for Child Health and Disorders, Chongqing, China. 4. China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, China. 5. Chongqing Key Laboratory of Pediatrics, Chongqing, China. 6. Guangzhou Women and Children's Medical Center, Guangzhou, China. 7. Division of Science and Technology, Beijing Normal University-Hongkong Baptist University United International College, Beijing, China. 8. Department of Pediatrics, Sichuan Provincial People's Hospital, Chengdu, China. 9. Department of Neurology, Children's Hospital of Chongqing Medical University, No.136 Zhongshan 2nd Road, Yu Zhong District, Chongqing, 400014, China. huyue915@163.com. 10. Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China. huyue915@163.com. 11. National Clinical Research Center for Child Health and Disorders, Chongqing, China. huyue915@163.com. 12. China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, China. huyue915@163.com. 13. Chongqing Key Laboratory of Pediatrics, Chongqing, China. huyue915@163.com.
Abstract
PURPOSE: To explore the efficacy and safety of intravenous immunoglobulin (IVIG) in the treatment of severe Japanese encephalitis (JE). METHODS: A retrospective study of 124 children diagnosed with the severe or very severe form of JE was undertaken. There were 62 cases in the IVIG group and control group. The efficacy, safety, and tolerability of IVIG were evaluated 3 days, as well as 1, 2, and 3 weeks after IVIG, respectively, and the prognosis was assessed at 6 months. RESULTS: Cox regression survival analysis suggested that the IVIG group reached the criteria for efficacious treatment faster than that in the control group. The duration of unconsciousness and the number of days of seizures, a dull response to light, the pyramidal sign, and meningeal-irritation sign in the IVIG group were shorter than those in the control group (p < 0.05). The number of complications occurring in the IVIG group (including gastrointestinal bleeding and pneumonia) was less than that in the control group (p < 0.05). Cox regression survival analysis suggested that age (p = 0.003) and imaging abnormalities (p = 0.042) had an effect on the efficacy of IVIG treatment. The Liverpool Outcome Score at 6 months showed that the prognosis of the IVIG group was better than that of the control group (p < 0.05). IVIG treatment was safe and tolerable. CONCLUSION: IVIG showed good efficacy, safety, and tolerance for treatment of the severe form of JE. The age and imaging abnormalities of patients affect the efficacy of IVIG treatment.
PURPOSE: To explore the efficacy and safety of intravenous immunoglobulin (IVIG) in the treatment of severe Japanese encephalitis (JE). METHODS: A retrospective study of 124 children diagnosed with the severe or very severe form of JE was undertaken. There were 62 cases in the IVIG group and control group. The efficacy, safety, and tolerability of IVIG were evaluated 3 days, as well as 1, 2, and 3 weeks after IVIG, respectively, and the prognosis was assessed at 6 months. RESULTS: Cox regression survival analysis suggested that the IVIG group reached the criteria for efficacious treatment faster than that in the control group. The duration of unconsciousness and the number of days of seizures, a dull response to light, the pyramidal sign, and meningeal-irritation sign in the IVIG group were shorter than those in the control group (p < 0.05). The number of complications occurring in the IVIG group (including gastrointestinal bleeding and pneumonia) was less than that in the control group (p < 0.05). Cox regression survival analysis suggested that age (p = 0.003) and imaging abnormalities (p = 0.042) had an effect on the efficacy of IVIG treatment. The Liverpool Outcome Score at 6 months showed that the prognosis of the IVIG group was better than that of the control group (p < 0.05). IVIG treatment was safe and tolerable. CONCLUSION: IVIG showed good efficacy, safety, and tolerance for treatment of the severe form of JE. The age and imaging abnormalities of patients affect the efficacy of IVIG treatment.
Authors: Penny Lewthwaite; Ashia Begum; Mong How Ooi; Brian Faragher; Boon Foo Lai; Indunil Sandaradura; Anand Mohan; Gaurav Mandhan; Pratibha Meharwade; S Subhashini; Gulia Abhishek; Asma Begum; Srihari Penkulinti; M Veera Shankar; R Ravikumar; Carolyn Young; Mary Jane Cardosa; V Ravi; See Chang Wong; Rachel Kneen; Tom Solomon Journal: Bull World Health Organ Date: 2010-04-19 Impact factor: 9.408
Authors: Grant L Campbell; Susan L Hills; Marc Fischer; Julie A Jacobson; Charles H Hoke; Joachim M Hombach; Anthony A Marfin; Tom Solomon; Theodore F Tsai; Vivien D Tsu; Amy S Ginsburg Journal: Bull World Health Organ Date: 2011-08-03 Impact factor: 9.408
Authors: Allison C German; Khin Saw Aye Myint; Nguyen Thi Hoang Mai; Ian Pomeroy; Nguyen Hoan Phu; John Tzartos; Peter Winter; Jennifer Collett; Jeremy Farrar; Alan Barrett; Anja Kipar; Margaret M Esiri; Tom Solomon Journal: Trans R Soc Trop Med Hyg Date: 2006-06-30 Impact factor: 2.184